David Cortez named associate director of basic science research at VICC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

David Cortez was named associate director for Basic Science Research at Vanderbilt-Ingram Cancer Center.

Cortez, the Richard Armstrong Professor of Biochemistry, joined Vanderbilt University in 2002. He is an expert in the field of DNA damage response and repair and made seminal discoveries about the mechanisms that maintain genome integrity.

Cortez is a member of the editorial boards for Cell Reports and Molecular and Cellular Biology. Cortez has been a co-leader of the Genome Maintenance Research Program since its inception in 2007 at VICC, and served as director of Graduate Studies in the Department of Biochemistry at Vanderbilt University for eight years.

Cortez replaces Scott Hiebert, professor of biochemistry and Hortense B. Ingram Professor of Cancer Research, who has served in the role since 2008. Hiebert is a member of the National Cancer Advisory Board.

Hiebert will continue in his role as associate director for shared resources and another interim leadership role to be announced soon. He will continue to focus on the molecular mechanisms of acute leukemia and the action of tumor suppressors in his own research program.

Table of Contents

YOU MAY BE INTERESTED IN

New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month.

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login